Literature DB >> 10961439

Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity.

I Veinbergs1, M Mante, M Mallory, E Masliah.   

Abstract

Excitotoxicity might play an important role in neurodegenerative disorders such as Alzheimer's disease. In the mouse brain, kainic acid (KA) lesioning results in neurodegeneration patterns similar to those found in human disease. For this study, two sets of experiments were performed in order to determine if Cerebrolysin ameliorates the alterations associated with KA administration. In the first set of experiments, mice received intraperitoneal KA injections followed by Cerebrolysin administration, while in the second, mice were pretreated with Cerebrolysin for 4 weeks and then challenged with KA. Behavioral testing in the water maze and assessment of neuronal structure by laser scanning confocal microscopy showed a significant protection against KA lesions in mice pretreated with Cerebrolysin. In contrast, mice that received Cerebrolysin after KA injections did not show significant improvement. This study supports the contention that Cerebrolysin might have a neuroprotective effect in vivo against excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961439     DOI: 10.1007/978-3-7091-6781-6_29

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  11 in total

1.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 2.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

3.  Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

Authors:  Edward Rockenstein; Kiren Ubhi; Edith Doppler; Philipp Novak; Herbert Moessler; Bin Li; Julie Blanchard; Inge Grundke-Iqbal; Khalid Iqbal; Michael Mante; Anthony Adame; Leslie Crews; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.

Authors:  Edward Rockenstein; Kiren Ubhi; Emiley Pham; Sarah Michael; Edith Doppler; Philipp Novak; Chandra Inglis; Michael Mante; Anthony Adame; X Anton Alvarez; Herbert Moessler; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2011-07-25       Impact factor: 4.164

5.  Spotlight on cerebrolysin in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

Review 6.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.

Authors:  Kiren Ubhi; Edward Rockenstein; Edith Doppler; Michael Mante; Anthony Adame; Christina Patrick; Margarita Trejo; Leslie Crews; Amy Paulino; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2009-02-28       Impact factor: 17.088

8.  Endogenous Kynurenine Aminotransferases Inhibitor is Proposed to Act as "Glia Depressing Factor" (GDF).

Authors:  Halina Baran; Berthold Kepplinger; Markus Draxler
Journal:  Int J Tryptophan Res       Date:  2010-05-11

9.  Cerebrolysin for vascular dementia.

Authors:  Shuhui Cui; Ning Chen; Mi Yang; Jian Guo; Muke Zhou; Cairong Zhu; Li He
Journal:  Cochrane Database Syst Rev       Date:  2019-11-11

10.  Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.

Authors:  Edward Rockenstein; Paula Desplats; Kiren Ubhi; Michael Mante; Jazmin Florio; Anthony Adame; Stefan Winter; Hemma Brandstaetter; Dieter Meier; Herbert Moessler; Eliezer Masliah
Journal:  J Exp Neurosci       Date:  2016-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.